Pathogenic fungi can cause varying degrees of severe disease in individuals with normal or impaired immunity, leading to death, long-term illness, and reduced life quality of infected patients. CD BioGlyco is committed to helping clients develop carbohydrate-based antifungal vaccines for the prevention of fungal infections.
The incidence of acute or chronic fungal diseases has increased significantly in the last decade. At the same time, drug resistance increase among clinical isolates of fungal pathogens increases the demand for the development of corresponding vaccines and therapeutic monoclonal antibodies. Antifungal vaccines are considered to be a medium to prevent or help treat fungal diseases in patients who need to be treated with immunosuppressive, transplants, or anticancer therapy. Therefore, an increasing number of researchers are focusing on the development of antifungal vaccines.
Polysaccharide components of the fungal cell wall which are not present in humans and mammals are considered promising targets for the development of antifungal immunotherapies. However, purified fungal antigens associated with cell wall polysaccharides are difficult to obtain from natural sources. Moreover, most of these polysaccharides are very heterogeneous, consisting of different antigenic factors and exhibiting different immunogenicity, thus the synthesis of complex oligosaccharide structures associated with polysaccharide antigens is important for the development of antifungal vaccines.
Fig.1 Structural organization and polysaccharide components of cell walls of Candida albicans, Cryptococcus neoformans and Aspergillus fumigatus. (Krylov, 2020)
CD BioGlyco has developed carbohydrate-based vaccines against different fungi using various polysaccharides on the fungal cell wall as targets for antifungal immunotherapy. Our services include but are not limited to:
We designed and constructed three-component glycoconjugate vaccines containing b-mannan related trisaccharide ([b-Man]3) and polypeptide C. albicans epitope Fba conjugated to a tetanus toxoid carrier IV.
We improved the vaccine by changing from natural polysaccharides to well-defined synthetic oligosaccharides and site-controlled conjugation methods.
CD BioGlyco has developed the potential of fungal cell wall polysaccharides as a basis for the development of glycoconjugate vaccines based on synthetic oligosaccharides to help our clients design and synthesize safe and effective antifungal vaccines. If you have a demand for our services, please contact us for more consultation.
Reference:
About Us
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.
Contact Us
